Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Quinazolines

abstract

  • Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients. At 250 mg/d, gefitinib had a favorable AE profile. Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC [corrected]

publication date

  • June 15, 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2003.10.038

PubMed ID

  • 12748244

Additional Document Info

start page

  • 2237

end page

  • 46

volume

  • 21

number

  • 12